How much weight is regained after stopping Wegovy?

In the STEP-1 extension trial, participants who had lost an average of 17.3% of body weight on Wegovy 2.4 mg over 68 weeks regained about 11.6 percentage points over the following year off medication, leaving a net loss of about 5.6% — roughly two-thirds of the original loss returned within a year.

How long does Wegovy stay in your system after your last shot?

Semaglutide (Wegovy's active ingredient) has a half-life of about 1 week. Following the standard 5-half-lives clearance convention, most of the drug is gone about 5 weeks after your last dose. Meaningful appetite suppression tends to fade earlier — usually within the first 2–3 weeks.

Is stopping Wegovy different from stopping Ozempic?

The pharmacokinetics are identical — both are semaglutide with the same ~1-week half-life. The main difference is dose: Wegovy peaks at 2.4 mg weekly for weight management, Ozempic peaks at 2 mg weekly for diabetes. Higher steady-state drug levels on Wegovy mean the appetite suppression being removed is somewhat larger, but the transition shape is the same.

Do I need to taper off Wegovy?

There is no FDA-labeled tapering protocol for Wegovy, and the WHO's December 2025 guideline explicitly notes that discontinuation evidence is limited. Some prescribers step down through the reverse titration schedule (2.4 → 1.7 → 1.0 → 0.5 → 0.25 mg); others stop directly. This is a conversation with your prescriber, not a proven better option either way.

How soon after stopping will I notice hunger coming back?

Most people describe distinctly increased hunger within 1–2 weeks of the last shot. The rebound tracks with drug clearance — as semaglutide levels drop, ghrelin (the hunger hormone) returns toward pre-treatment baseline. Full appetite return usually lands somewhere in weeks 4–8.

Will I regain all the weight I lost on Wegovy?

Not necessarily. STEP-1 extension participants regained about two-thirds of their loss on average over one year — but that's a group average, and the distribution is wide. Habit consistency during and after treatment (protein target, meal structure, resistance activity) is one of the largest sources of variance in individual outcomes.

What Actually Happens When You Stop Wegovy

Written by the GLP-1 Coach editorial team. Last updated August 14, 2026.

Wegovy is semaglutide at its highest approved dose — a 2.4 mg weekly injection specifically labeled for chronic weight management. It's the same molecule as Ozempic, but at a target dose engineered for maximum appetite suppression rather than for glycemic control. That difference matters when the medication is stopped: the pharmacokinetics are the same, but the amount of appetite suppression being removed is larger.

Here's what the actual data shows about the year after stopping Wegovy, and how the transition typically unfolds.

What is Wegovy, exactly, and why does the dose matter for stopping?

Wegovy is Novo Nordisk's brand for semaglutide 2.4 mg — the same active ingredient as Ozempic (which peaks at 2 mg for type 2 diabetes) and Rybelsus (the oral formulation). The 2.4 mg dose is reached through a standard titration schedule: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg, with each step held for approximately 4 weeks. Most Wegovy users spend 16 to 20 weeks in the titration phase before reaching maintenance.

The reason the dose matters for the stopping conversation: higher steady-state semaglutide levels produce stronger appetite suppression, which means the physiological effect being removed at cessation is larger on Wegovy than on lower-dose semaglutide. That doesn't change the shape of the transition — hunger comes back on the same pharmacokinetic clock either way — but it can change the intensity of the rebound.

What does the STEP-1 extension trial actually show?

The clearest published data on stopping Wegovy comes from the extension of the STEP-1 pivotal trial, published in Diabetes, Obesity and Metabolism in 2022. STEP-1 participants who received 68 weeks of Wegovy 2.4 mg were followed for another year after cessation. The headline numbers:

Timepoint	Average body weight change from baseline
Week 68 (end of active treatment)	−17.3%
Week 120 (52 weeks off medication)	−5.6%
Net regained during off-treatment year	+11.6 percentage points

Interpretation: participants regained roughly two-thirds of the weight they'd lost within one year of stopping. About a third of the original loss was retained on average.

The comparison group — participants who continued Wegovy through week 120 — maintained substantially more of their loss. The gap between the two groups over the follow-up year is essentially the pure pharmacological contribution of the medication, disentangled from any behavioral effects that continued after cessation.

Timeline of the transition after your last Wegovy dose

Because semaglutide has a ~1-week half-life, drug clearance and appetite return follow a predictable curve:

Time since last dose	Approximate drug level	What most people notice
Week 1	~50% remaining	GI side effects fade; appetite still meaningfully suppressed
Week 2	~25% remaining	Distinctly stronger hunger; ghrelin rebounds
Week 3	~12.5% remaining	Portion control by feel becomes less reliable; food noise returning
Week 4	~6% remaining	Appetite close to pre-treatment baseline; 1–3% weight uptick common
Week 5+	Functionally cleared	Habits are the primary protection now

The 1–3% weight uptick most people see in weeks 4–6 is not fat regain — it's largely rehydration and glycogen restoration as food volume rises back toward pre-treatment levels. The actual regain trajectory typically becomes visible in the trend line from about week 6 onward.

Why the first 8 weeks off Wegovy set the pattern for the next year

The STEP-1 extension shows the year-long regain trajectory. What it doesn't show is that the shape of the curve isn't uniform across the year — the habit patterns established in the first 8 weeks off medication are what determine whether the curve is steep or gentle.

The mechanism is straightforward: appetite return over weeks 1–8 is the physiological given (semaglutide is clearing whether you like it or not). What varies is how a person responds. If protein intake, meal structure, and resistance activity were established during Wegovy treatment and carry forward through the transition, the regain curve tends to be shallower. If those habits were passive on medication (relying on appetite suppression to do the work), the curve tends to be steeper.

This is the reason the eight-week window post-cessation gets so much attention in the obesity medicine literature: it's the window where course-correction is still small and cheap.

Wegovy vs Ozempic: does it matter which one you were on?

The molecule is the same. The half-life is the same. The drug clearance timeline is the same. What differs:

	Wegovy	Ozempic (at 2 mg)
Target maintenance dose	2.4 mg weekly	2 mg weekly
Steady-state drug level	Higher	Lower
Typical appetite suppression at maintenance	Stronger	Somewhat weaker
Typical intensity of appetite rebound after stopping	Larger absolute change	Smaller absolute change
Regain trajectory after cessation	STEP-1 extension data (~2/3 regained over 1 year)	Less directly measured; likely similar directional pattern

If you were on Ozempic 0.5 mg or 1 mg (the more common Ozempic maintenance doses) rather than 2 mg, the appetite rebound is generally smaller because the appetite suppression being removed is smaller. But the shape of the transition — hunger returning on a 5-week pharmacokinetic clock, weight trajectory revealing itself around week 4–6, habits carrying the loss forward or not — is essentially the same. For people stopping tirzepatide (Mounjaro or Zepbound) instead of semaglutide, the clearance is faster and the rebound sharper — see what happens when you stop Mounjaro or Zepbound for the SURMOUNT-4 data.

Do I need to taper Wegovy?

This is a distinct decision from when to stop, and the honest answer is that there is no evidence-based protocol.

Neither Novo Nordisk's prescribing information nor the WHO's December 2025 GLP-1 guideline includes a formal tapering schedule for Wegovy. The WHO guideline says plainly that "limited data are currently available to inform practice around decisions about, or the health impact of, discontinuation."

Some prescribers step down through the reverse of the titration schedule (2.4 → 1.7 → 1.0 → 0.5 → 0.25 mg, with each step held for roughly 4 weeks). The rationale is physiologically reasonable — a slower step-down may soften the appetite rebound and give more chances to notice regain drift early — but it hasn't been shown in a controlled trial to change outcomes vs an abrupt stop. A full breakdown of the evidence (or lack thereof) for each approach is in tapering off GLP-1: cold-turkey vs step-down.

If cost, coverage, and adherence favor tapering, it's a reasonable choice. If any of those don't, stopping directly is not dangerous — the STEP-1 extension used abrupt cessation as its study design and the resulting regain patterns are what the trial reported.

What actually protects the weight loss?

Two levers with the strongest support:

Protein target at 0.7–1 g per pound of goal body weight, held consistently through the appetite-return window. This is the single most important habit for protecting lean mass while food intake climbs back toward pre-treatment volumes.
Resistance activity two or more times per week. Even light resistance work meaningfully reduces the muscle loss that accompanies weight-cycling and supports resting metabolic rate during the transition.

Both are far more predictive of the individual regain trajectory than any decision about tapering or the choice of stopping method. The STEP-1 extension didn't measure habit consistency directly, but the wide variance in individual outcomes within the trial almost certainly reflects, in part, the wide variance in what people did behaviorally after their last dose.

The bottom line

Bottom line: Stopping Wegovy sets off a predictable ~5-week semaglutide clearance and, on average, about two-thirds of the weight lost returns over the following year (STEP-1 extension). The transition is the same shape as stopping Ozempic — same molecule, same clearance clock — but the higher 2.4 mg maintenance dose means the appetite suppression being removed is larger. Tapering has no proven benefit vs stopping directly; habit consistency in the first 8 weeks is what most reliably shapes the year-long trajectory.

Related tool: our free post-therapy timeline calculator applies this data to your specific last-dose date.

Final Thoughts

The STEP-1 extension is the closest thing to a definitive dataset on what happens after Wegovy — but it's a description of a group average, not a prescription for an individual trajectory. The two-thirds-regain figure is not a prediction of what will happen to any specific person; it's the midpoint of a wide distribution shaped substantially by the habits people carried out of active treatment.

If you're on Wegovy now and thinking about the transition, the highest-leverage thing you can do isn't planning the exact stop date. It's making sure the protein consistency, meal structure, and resistance activity that will need to carry the loss forward are actually in place while the drug is still doing its work. For a broader look at the full post-GLP-1 transition — including what to do in the first 8–12 weeks — see life after Ozempic: how to maintain weight loss after stopping. And if you have type 2 diabetes, the A1C rebound after semaglutide deserves its own plan — see blood sugar and A1C after stopping Ozempic. If you're already off Wegovy and noticing hunger and cravings returning, that's the expected timeline for a semaglutide-clearing system — not a signal that something has gone wrong.

The medication ends its contribution at your last dose. What happens after is a habit and physiology story, and both are more responsive to structure than most people expect.

Related:

This article is educational and not a substitute for medical advice. Decisions about stopping, tapering, or continuing Wegovy should be made with the prescriber managing your care.

Sources: Wilding et al., STEP 1 extension, Diabetes, Obesity and Metabolism 2022; Wilding et al., STEP 1 primary trial, NEJM 2021; Wegovy prescribing information, FDA; WHO Global Guideline on GLP-1 Medicines for Obesity, December 2025.